Oramed Pharmaceuticals Inc.

NASDAQ:ORMP

Biotechnology

Healthcare
$3.89 +0.79%

+$0.03 today

Market cap
$169.16M
Beta
1.24
P/E (TTM)
1.4
EPS (TTM)
$2.70
Dividend yield
6.54%
52W Low $1.98High $5.01

Volume 0.16M

Average 0.16M

ORMP Net Income

Bottom-line profit after all expenses, interest, and taxes.

Oramed Pharmaceuticals Inc.NASDAQ: ORMP

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income turns positive

Q1 FY2026 net income was $38.31M, compared with -$7.64M a year earlier. Trailing-twelve-month net income was $110M.

Context

  • Net income amounted to 3202.5% of revenue in FY2025.
  • Net income increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 1 analysts of $189.61M (+196.0%) for the fiscal year ending Dec 2026, a slowdown from the +435.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$38.31M+282.8% QoQ
Last fiscal yearDec 2025
$64.05M+435.3% YoY
LTMMar 2026
$110M+489.6% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+601.3%+37.5%-563.8 pp
1 year+435.3%+196.0%-239.3 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
64.05M USD
Year-over-year change
+435.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How ORMP compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +489.6% is the highest of 11, against a peer median of -11.7%.
ORMP Competitors
Net Income for ORMP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$110M USD+489.6%——
COYACoya Therapeutics, Inc.LTM Mar 2026-$21.13M USD-23.3%—266.1%
OVIDOvid Therapeutics Inc.LTM Mar 2026-$24.17M USD+3.2%—339.3%
CLNNClene Inc.LTM Mar 2026-$33.51M USD-15.3%—25009.7%
CNTXContext Therapeutics Inc.LTM Mar 2026-$40.23M USD-45.6%——
IFRXInflaRx N.V.LTM Mar 2026-€42.91M EUR+4.0%—146303.9%
KLRSKalaris Therapeutics IncLTM Mar 2026-$44.1M USD+38.9%——
IMAImageneBio IncLTM Mar 2026-$45.07M USD-8.1%——
STTKShattuck Labs, Inc.LTM Mar 2026-$49.87M USD+29.4%—4987.4%
CNTBConnect Biopharma Holdings LimitedFY2025-$55.48M USD-255.0%—86687.5%
MGNXMacroGenics, Inc.LTM Mar 2026-$70.36M USD-26.1%—44.8%
Peer median (excluding ORMP) —-11.7%—4987.4%

Competitors are the stored peer set for ORMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Aug 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.7M2.7M1.34M02M
Cost of Revenue000193K1.99M
Gross Profit2.7M2.7M1.34M(193K)13K
Gross Margin100.0%100.0%100.0%—0.7%
Research & Development20.99M27.64M8.97M6.32M6.38M
Selling, General & Admin5.94M15.66M8.14M6.46M8.72M
Operating Expenses26.93M43.3M17.11M12.78M15.1M
Depreciation & Amortization77K3.62M196K193K121K
EBITDA(25.04M)(36.98M)7.32M(14.87M)75.45M
EBITDA Margin-926.3%-1368.0%546.3%—3772.2%
Operating Income(24.22M)(40.6M)(15.77M)(12.78M)(15.09M)
Operating Margin-896.2%-1502.0%-1176.8%—-754.4%
Interest Income347K3.57M8.03M02.37M
Interest Expense6K03.58M853K0
Other Income / Expenses893K2.93M20.86M(3.14M)90.41M
Income Before Tax(22.99M)(37.66M)5.09M(15.92M)75.32M
Pre-Tax Margin-850.5%-1393.4%379.7%—3766.2%
Income Tax Expense(2.88M)100K03.18M11.31M
Net Income(22.24M)(37.76M)5.53M(19.1M)64.05M
Net Margin-822.7%-1397.1%412.3%—3202.5%
EPS (Basic)(0.78)(0.97)0.14(0.47)1.53
EPS (Diluted)(0.78)(0.97)0.14(0.47)1.50
Weighted Avg Shares28.47M39M40.32M40.83M41.4M
Weighted Avg Shares (Diluted)28.47M39M40.57M40.83M42.42M

Oramed Pharmaceuticals Inc.

NASDAQ:ORMP

Intrinsic Alpha fair value

Locked

Current Price

$3.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.